论文部分内容阅读
目的对肥胖2型糖尿病患者采取利拉鲁肽联合二甲双胍共同治疗的方案,并对其临床的效果进行探究与评价。方法 68例肥胖2型糖尿病患者,按其入院先后顺序平均分为试验组与对照组,每组34例。对照组予以二甲双胍进行治疗,试验组则在使用二甲双胍的同时,给予利拉鲁肽联合治疗方案。对比两组患者治疗前后的空腹血糖、餐后2 h血糖、体质量指数(BMI)变化、糖化血红蛋白(Hb A1c)、血脂(甘油三酯、总胆固醇、低密度脂蛋白)及经过治疗后两组患者的不良反应情况。结果治疗前,两组患者的空腹血糖、餐后2 h血糖、BMI指数比较,差异无统计学意义(P>0.05);经过治疗后,试验组的患者空腹血糖、餐后2 h血糖、BMI指数、Hb A1c、血脂均明显优于对照组,差异有统计学有意义(P<0.05);经过治疗后,试验组发生低血糖2例,对照组发生低血糖11例,两组比较差异有统计学意义(P<0.05)。结论肥胖2型糖尿病的患者采取利拉鲁肽与二甲双胍共同治疗后,不良反应的发生率明显下降且体内的血糖值也得到了有效控制,效果显著。
Objective To study the co-treatment of liraglutide and metformin in obese type 2 diabetic patients and explore its clinical efficacy. Methods Sixty-eight obese patients with type 2 diabetes mellitus were divided equally into experimental group and control group according to their order of admission, with 34 cases in each group. Patients in the control group were treated with metformin, while those in the test group were treated with metformin at the same time as the combination regimen of liraglutide. Fasting blood glucose, postprandial blood glucose at 2 hours, body mass index (BMI), Hb A1c, blood lipid (triglyceride, total cholesterol and low density lipoprotein) Group of patients with adverse reactions. Results Before treatment, there was no significant difference in fasting blood glucose, postprandial 2-h blood glucose and BMI between the two groups (P> 0.05). After treatment, the fasting blood glucose, postprandial blood glucose 2 h, BMI Index, Hb A1c and lipids were significantly better than the control group, the difference was statistically significant (P <0.05); after treatment, hypoglycemia in the experimental group in 2 cases, the control group occurred in 11 cases of hypoglycemia, the difference was Statistical significance (P <0.05). Conclusion The incidence of adverse reactions was significantly decreased in patients with obese type 2 diabetes treated with liraglutide and metformin, and the blood glucose level in the body was also effectively controlled with a significant effect.